Fred Alger Management LLC Has $2.11 Million Holdings in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Key Points

• Fred Alger Management LLC reduced its stake in Centessa Pharmaceuticals by 23.1% in the 1st quarter, now owning approximately 0.11% of the company, valued at $2.1 million.
• Institutional ownership of Centessa Pharmaceuticals stands at 82.01%, with GAMMA Investing LLC significantly increasing its share by 1,509.6% during the same period.
• Wall Street analysts maintain a generally positive outlook on Centessa Pharmaceuticals, with the stock carrying an average rating of "Buy" and a consensus target price of $31.45.

Fred Alger Management LLC decreased its position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA - Free Report) by 23.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 146,398 shares of the company's stock after selling 44,053 shares during the quarter. Fred Alger Management LLC owned 0.11% of Centessa Pharmaceuticals worth $2,105,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in CNTA. GF Fund Management CO. LTD. bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter worth about $31,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company's stock worth $46,000 after purchasing an additional 3,194 shares during the last quarter. Osterweis Capital Management Inc. bought a new stake in shares of Centessa Pharmaceuticals in the 1st quarter worth about $47,000. Barclays PLC grew its holdings in shares of Centessa Pharmaceuticals by 1,414.9% in the 4th quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after purchasing an additional 4,952 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Centessa Pharmaceuticals in the 1st quarter worth about $147,000. Institutional investors own 82.01% of the company's stock.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Monday, July 21st. The stock was sold at an average price of $15.92, for a total transaction of $875,600.00. Following the completion of the sale, the chief executive officer directly owned 221,017 shares of the company's stock, valued at approximately $3,518,590.64. This represents a 19.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mario Alberto Accardi sold 7,000 shares of the stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $20.00, for a total value of $140,000.00. Following the sale, the insider directly owned 205,566 shares of the company's stock, valued at approximately $4,111,320. The trade was a 3.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 248,114 shares of company stock worth $4,058,854 in the last quarter. Company insiders own 7.09% of the company's stock.

Centessa Pharmaceuticals Trading Up 1.3%

Shares of NASDAQ:CNTA traded up $0.29 during mid-day trading on Monday, reaching $22.10. The stock had a trading volume of 226,149 shares, compared to its average volume of 1,017,387. The firm has a market cap of $2.96 billion, a PE ratio of -12.38 and a beta of 1.47. The firm has a 50 day simple moving average of $16.74 and a two-hundred day simple moving average of $14.62. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $9.60 and a twelve month high of $23.24.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.03). On average, research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CNTA. Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a "strong-buy" rating in a research report on Wednesday, September 3rd. Wells Fargo & Company began coverage on shares of Centessa Pharmaceuticals in a research report on Wednesday, September 3rd. They set an "overweight" rating and a $31.00 price target on the stock. Truist Financial began coverage on shares of Centessa Pharmaceuticals in a research report on Monday, July 21st. They set a "buy" rating and a $30.00 price target on the stock. Wall Street Zen downgraded shares of Centessa Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, August 16th. Finally, Chardan Capital reiterated a "buy" rating and set a $30.00 price target on shares of Centessa Pharmaceuticals in a research report on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $32.70.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.